Company Overview of Embera NeuroTherapeutics, Inc.
Embera NeuroTherapeutics, Inc., a development-stage pharmaceutical company, develops treatments for smoking cessation, cocaine dependence, and other addictions. It engages in developing EMB-001, an addiction treatment that includes benzodiazepine oxazepam and cortisol synthesis inhibitor metyrapone medications, which targets the stress response system and specific brain functions that leads to craving and relapse associated with these disorders, as well as acts by modulating various stress-related pathways to reduce the craving that drives addictions. The company was founded in 2005 and is based in Sudbury, Massachusetts.
29 Babe Ruth Drive
Sudbury, MA 01776
Founded in 2005
Key Executives for Embera NeuroTherapeutics, Inc.
Embera NeuroTherapeutics, Inc. Key Developments
Similar Private Companies By Industry
|Ceva Biomune||United States|
|Watson Laboratories, Inc.||United States|
|PTS Intermediate Holdings LLC||United States|
|Boehringer Ingelheim Vetmedica, Inc.||United States|
|BioValve Technologies, Inc.||United States|
Recent Private Companies Transactions
December 19, 2014
To contact Embera NeuroTherapeutics, Inc., please visit emberaneuro.com. Company data is provided by Capital IQ. Please use this form to report any data issues.